Laura Pizzuti Selected Research

Male Breast Neoplasms (Male Breast Cancer)

10/2016	HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes.
11/2015	Androgen receptor and antiandrogen therapy in male breast cancer.
5/2015	Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis.
3/2015	Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study.
11/2014	Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series.
9/2014	Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations.
8/2013	Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Laura Pizzuti Research Topics

Disease

51	Breast Neoplasms (Breast Cancer) 01/2022 - 07/2006
43	Neoplasms (Cancer) 12/2021 - 01/2012
9	Triple Negative Breast Neoplasms 01/2021 - 12/2015
8	Neoplasm Metastasis (Metastasis) 01/2022 - 05/2013
7	Male Breast Neoplasms (Male Breast Cancer) 10/2016 - 08/2013
4	Uterine Cervical Neoplasms (Cancer of the Cervix) 04/2021 - 01/2014
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2020 - 01/2012
4	Disease Progression 09/2019 - 08/2013
4	Stomach Neoplasms (Stomach Cancer) 01/2018 - 09/2013
2	Adenocarcinoma of Lung 12/2021 - 11/2019
2	Obesity 11/2020 - 10/2016
2	Brain Neoplasms (Brain Tumor) 04/2020 - 01/2019
2	Carcinoma (Carcinomatosis) 04/2020 - 01/2014
2	Ataxia Telangiectasia (Louis Bar Syndrome) 11/2019 - 01/2019
2	Cardiotoxicity 01/2019 - 01/2014
2	Ovarian Neoplasms (Ovarian Cancer) 02/2018 - 08/2013
2	Rare Diseases (Rare Disease) 08/2017 - 11/2014
2	Ovarian Epithelial Carcinoma 01/2016 - 08/2013
1	Vulvar Neoplasms (Vulvar Cancer) 08/2021
1	Pathologic Complete Response 09/2020
1	Renal Cell Carcinoma (Grawitz Tumor) 04/2020
1	Melanoma (Melanoma, Malignant) 04/2020
1	Colonic Neoplasms (Colon Cancer) 04/2020
1	Squamous Cell Carcinoma of Head and Neck 04/2020
1	Head and Neck Neoplasms (Head and Neck Cancer) 04/2020
1	COVID-19 01/2020
1	Lung Neoplasms (Lung Cancer) 01/2020
1	Anaplasia 01/2019
1	Ataxia (Dyssynergia) 01/2019

Drug/Important Bio-Agent (IBA)

14	Hormones (Hormone)IBA 01/2022 - 08/2013
12	Trastuzumab (Herceptin)FDA Link 11/2021 - 05/2013
10	Biomarkers (Surrogate Marker)IBA 04/2020 - 10/2014
9	Immune Checkpoint InhibitorsIBA 12/2021 - 11/2017
8	Phenobarbital (Luminal)FDA Link 11/2021 - 10/2014
8	AnthracyclinesIBA 09/2020 - 04/2011
7	Taxoids (Taxanes)IBA 09/2020 - 05/2013
6	human ERBB2 proteinIBA 01/2021 - 10/2014
6	pertuzumabIBA 01/2021 - 01/2017
5	eribulin FDA Link 01/2021 - 01/2014
5	Phosphotransferases (Kinase)IBA 11/2019 - 01/2012
5	Estrogen ReceptorsIBA 09/2019 - 10/2014
5	Glucose (Dextrose)FDA LinkGeneric 02/2018 - 11/2014
4	Fulvestrant (Faslodex)FDA Link 11/2021 - 08/2017
4	Biological ProductsIBA 08/2021 - 01/2014
4	Everolimus FDA Link 12/2020 - 01/2017
4	exemestane (Aromasin)FDA Link 12/2020 - 01/2017
4	Progesterone Receptors (Progesterone Receptor)IBA 04/2017 - 07/2006
4	Gonadotropin-Releasing Hormone (GnRH)FDA Link 05/2015 - 08/2013
3	Cyclin-Dependent Kinase 4IBA 01/2022 - 12/2020
3	DNA (Deoxyribonucleic Acid)IBA 04/2021 - 12/2015
3	Estrogens (Estrogen)FDA Link 01/2021 - 07/2006
3	palbociclibIBA 01/2021 - 01/2019
3	Ado-Trastuzumab EmtansineIBA 01/2021 - 01/2017
3	PlatinumIBA 04/2020 - 08/2013
3	Capecitabine (Xeloda)FDA Link 09/2019 - 05/2013
3	Androgen Antagonists (Antiandrogens)IBA 11/2015 - 11/2014
3	Aromatase InhibitorsIBA 05/2015 - 08/2013
2	ribociclibIBA 01/2022 - 01/2021
2	Pharmaceutical PreparationsIBA 01/2021 - 03/2015
2	Indicators and Reagents (Reagents)IBA 11/2020 - 01/2016
2	NivolumabIBA 04/2020 - 01/2019
2	Proteins (Proteins, Gene)FDA Link 11/2019 - 01/2019
2	Antineoplastic Agents (Antineoplastics)IBA 01/2019 - 02/2015
2	ErbB Receptors (EGF Receptor)IBA 01/2019 - 01/2014
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2018 - 06/2017
2	Bevacizumab (Avastin)FDA Link 01/2018 - 06/2017
2	Oncogene Proteins (Oncogene Protein)IBA 06/2016 - 01/2016
2	Androgen Receptors (Androgen Receptor)IBA 11/2015 - 11/2014
2	Cyproterone AcetateIBA 05/2015 - 11/2014
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2014 - 08/2013
2	Docetaxel (Taxotere)FDA Link 10/2014 - 09/2013
2	liposomal doxorubicin (Doxil)FDA Link 01/2014 - 04/2011
2	Fatty Acid Synthases (Fatty Acid Synthase)IBA 07/2007 - 07/2006
1	GenieIBA 12/2021
1	abemaciclibIBA 01/2021
1	Epidermal Growth Factor (EGF)IBA 01/2021
1	GlucocorticoidsIBA 01/2021
1	LigandsIBA 09/2020
1	atezolizumabIBA 09/2020
1	Carboplatin (JM8)FDA LinkGeneric 09/2020
1	B7-H1 AntigenIBA 04/2020
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 11/2019
1	AutoantibodiesIBA 01/2019
1	Histones (Histone)IBA 01/2019
1	taxaneIBA 01/2019
1	Tamoxifen FDA LinkGeneric 01/2019
1	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 02/2018
1	Factor VIII (Coagulation Factor VIII)IBA 01/2018
1	antithrombin III-protease complexIBA 01/2018
1	fibrin fragment D (D-dimer)IBA 01/2018
1	Plasminogen InactivatorsIBA 01/2018

Therapy/Procedure

29	Therapeutics 01/2022 - 08/2013
18	Drug Therapy (Chemotherapy) 08/2021 - 07/2013
12	Neoadjuvant Therapy 01/2021 - 01/2014
4	Immunotherapy 12/2021 - 03/2014
2	Combination Drug Therapy (Combination Chemotherapy) 03/2015 - 10/2014
1	Radiotherapy 01/2021
1	Drug Tapering 01/2021
1	Contraindications 01/2019
1	Metronomic Administration 01/2019